Table 1. Patient demographics.
| Characteristic | Mean (SD), median (IQR), or n (%) |
|---|---|
| Age, years; mean (SD) | 64 (8) |
| PSA, μg/l; median (IQR) | 6.9 (5.1–9.0) |
| Free PSA, percent; median (IQR) | 15 (11–20) |
| Prostate volume, ml; median (IQR) | 39 (30–54) |
| PSA density, μg/l/ml; median (IQR) | 0.17 (0.12–0.24) |
| 5-ARI; n (%) | 34 (10) |
| DRE positive; n (%) | 86 (25) |
| TRUS biopsy positive; n (%) | 85 (25) |
| IMPROD bpMRI Likert score; n (%) | |
| 1 | 34 (10) |
| 2 | 41 (12) |
| 3 | 66 (20) |
| 4 | 59 (17) |
| 5 | 138 (41) |
| Biopsy result | |
| Benign; n (%) | 131 (39) |
| Cancer; n (%) | |
| GGG 1/Gleason score 3 + 3 | 61 (18) |
| GGG 2/Gleason score 3 + 4 | 58 (17) |
| GGG 3/Gleason score 4 + 3 | 36 (11) |
| GGG 4/Gleason score 4 + 4/3 + 5/5 + 3 | 20 (6) |
| GGG 5/Gleason score 4 + 5/5 + 5 | 32 (9) |
5-ARI, 5-alpha reductase inhibitor; bpMRI, biparametric magnetic resonance imaging; DRE, digital rectal examination; GGG, 2014 International Society of Urological Pathology Gleason grade group; PSA, prostate specific antigen; TRUS, transrectal ultrasound-guided.